Biogenerix AG
Records under this name other than the patents Biogenerix AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,207,112 | Liquid formulation of G-CSF conjugate Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,546,328 | Liquid Formulation of G-Csf Conjugate Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,222,081 | Method of Producing and Purifying an Active Soluble Sialyltransferase Formerly held In force · High confidence | In force | High confidence | |
| US 7,468,351 | Erythropoietin solution formulation Formerly held Term ended Term ended Dec 22, 2024 · USPTO record | Term ended | Term ended Dec 22, 2024 | USPTO record |
| US 9,050,304 | Methods of Treatment Using Glycopegylated G-Csf Formerly held Lapsed on the fee record Ended Jun 9, 2023 · Medium confidence | Lapsed on the fee record | Ended Jun 9, 2023 | Medium confidence |
| US 9,029,331 | Glycopegylated Granulocyte Colony Stimulating Factor Formerly held Lapsed on the fee record Ended May 12, 2023 · High confidence | Lapsed on the fee record | Ended May 12, 2023 | High confidence |
| US 8,946,161 | Method of treatment using stable liquid formulation of G-CSF Formerly held Lapsed on the fee record Ended Feb 3, 2023 · USPTO record | Lapsed on the fee record | Ended Feb 3, 2023 | USPTO record |
| US 8,703,123 | Method for obtaining biologically active recombinant human G-CSF Formerly held Lapsed on the fee record Ended Apr 22, 2022 · USPTO record | Lapsed on the fee record | Ended Apr 22, 2022 | USPTO record |
| US 8,562,967 | Stable liquid formulations of G-CSF Formerly held Lapsed on the fee record Ended Oct 22, 2021 · USPTO record | Lapsed on the fee record | Ended Oct 22, 2021 | USPTO record |
| US 7,524,655 | Synthesis of oligosaccharides, glycolipids, and glycoproteins using bacterial glycosyltransferases Formerly held Lapsed on the fee record Ended Apr 28, 2021 · USPTO record | Lapsed on the fee record | Ended Apr 28, 2021 | USPTO record |